Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Accounts Payables (2020 - 2025)

Historic Accounts Payables for Inhibikase Therapeutics (IKT) over the last 6 years, with Q3 2025 value amounting to $620528.0.

  • Inhibikase Therapeutics' Accounts Payables fell 7546.56% to $620528.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $620528.0, marking a year-over-year decrease of 7546.56%. This contributed to the annual value of $943019.0 for FY2024, which is 4580.51% up from last year.
  • Inhibikase Therapeutics' Accounts Payables amounted to $620528.0 in Q3 2025, which was down 7546.56% from $2.7 million recorded in Q2 2025.
  • Over the past 5 years, Inhibikase Therapeutics' Accounts Payables peaked at $21.8 million during Q1 2023, and registered a low of $620528.0 during Q3 2025.
  • Moreover, its 5-year median value for Accounts Payables was $2.5 million (2021), whereas its average is $5.1 million.
  • In the last 5 years, Inhibikase Therapeutics' Accounts Payables skyrocketed by 74399.7% in 2022 and then tumbled by 9050.58% in 2023.
  • Over the past 5 years, Inhibikase Therapeutics' Accounts Payables (Quarter) stood at $1.1 million in 2021, then grew by 5.63% to $1.2 million in 2022, then plummeted by 43.82% to $646767.0 in 2023, then soared by 45.81% to $943019.0 in 2024, then tumbled by 34.2% to $620528.0 in 2025.
  • Its Accounts Payables was $620528.0 in Q3 2025, compared to $2.7 million in Q2 2025 and $1.7 million in Q1 2025.